Related Experiment Video
Updated: May 23, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma
Michael A Postow1, James Harding, Jedd D Wolchok
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Abstract:
Insight into the mechanisms of anti-tumor immunity has generated great enthusiasm for the treatment of patients with advanced melanoma. Particularly, negative regulators of the immune system, called immunologic checkpoints, have been found to play important roles in restraining otherwise effective anti-tumor immunologic responses. Therapies that target these negative regulator checkpoints, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have demonstrated promising clinical results. Treatment is generally well tolerated, but a novel spectrum of side effects, termed immune-related adverse events, has been experienced. Unfortunately, not all patients respond to these therapies, and evaluation of biomarkers predictive of response is ongoing. Based on their unique mechanisms of action, radiographic assessment of response differs from methods traditionally applied to cytotoxic chemotherapy. We expect ongoing and future efforts combining agents that target immunologic checkpoints with other immunotherapeutic approaches, targeted therapy, chemotherapy, and radiotherapy may additionally be beneficial.
Insights
Immunotherapies targeting immune checkpoints like CTLA-4 and PD-1 show promise for advanced melanoma. Further research is exploring biomarkers and combination therapies to improve patient response and outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Advanced melanoma treatment has seen progress with immunotherapies.
- Immune checkpoints (e.g., CTLA-4, PD-1) are key regulators of anti-tumor immunity.
- Targeting these checkpoints offers a novel therapeutic strategy.
Purpose of the Study:
- To review the mechanisms and clinical efficacy of immunotherapies targeting immune checkpoints in advanced melanoma.
- To discuss the associated immune-related adverse events and challenges in treatment response.
- To explore future directions in combination therapies and biomarker development.
Main Methods:
- Review of clinical trial data and scientific literature on immune checkpoint inhibitors.
- Analysis of mechanisms of action for CTLA-4 and PD-1 inhibitors.
- Discussion of response assessment and emerging therapeutic strategies.
Main Results:
- Immune checkpoint inhibitors (CTLA-4, PD-1) demonstrate promising clinical results in advanced melanoma.
- Treatment is generally well-tolerated but associated with immune-related adverse events.
- Patient response varies, highlighting the need for predictive biomarkers.
Conclusions:
- Immunotherapies targeting immune checkpoints represent a significant advancement in melanoma treatment.
- Ongoing research focuses on identifying predictive biomarkers and optimizing combination therapies.
- Future strategies may involve combining checkpoint inhibitors with other treatment modalities for enhanced efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:17The Tumor Microenvironment